Nancy Wexler visits Ionis Pharmaceuticals to meet the people making the magic happen!

1st Row from left to right- Kristina Bowyer, Leo Sahelijo, Tiffany Baumann, Nancy Wexler, Anne Smith, Holly Kordasiewicz

2nd row left to right- Patrick Cauntay, Chrissa Dwyer (hidden),  Bethany Fitzsimmons, Eric Swayze, Paul Goldberg, Rojer Lane

Eventually C. Frank Bennett, 2018 Leslie Gehry Brenner Prize for Innovation in Science recipient, steps in for a requisite Nancy Wexler hug!

Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science

Bennett, Frank HD2018.JPG

We are thrilled to present Frank Bennett with the 2018 Leslie Gehry Brenner Prize for Innovation in Science for his innovative work in bringing us a totally novel class of drugs. We recognize the truly pathbreaking and monumental promise of Frank’s creativity to mold DNA in a way that the toxic HD protein is silenced from mucking up the works in our brain cells. His innovation applies to other brain battering diseases like Alzheimer's, Parkinson's, Lou Gehrig's (ALS) and others. Frank’s novel insight to use the body’s own molecular capacity to create new medicine make him an HD pioneer. His accomplishments honor the spirit and memory of Leslie Gehry by embodying originality, spontaneity, precision and rigor – all critical attributes in a scientist.

Read the Ionis press release.

Update from Roche/Genentech on RG6042 Huntington’s disease global development program: Two clinical studies to begin by end of 2018

roche-genentech.png

Over the past months we and our partner Ionis Pharmaceuticals have been heavily engaged with communities around the world (patient groups, medical professionals, Health Authorities and payers) to collaborate and build the RG6042 global development programme and upcoming studies. We are eager for RG6042 to advance into further clinical development. In addition, as announced last month, the European Medicines Agency granted RG6042 PRIME (“PRIority MEdicine”) designation, which provides promising medicines enhanced interactions with the agency and the potential for accelerated evaluation.

READ THE FULL PRESS RELEASE AND LEARN ABOUT THE NEXT STEPS, ONGOING AND UPCOMING CLINICAL STUDIES FOR THE GLOBAL RG6042 DEVELOPMENT PROGRAM.

Exciting news from Ionis Pharmaceuticals! Potentially faster approval for HTTRx!

Ionis Pharmaceuticals.jpg

Ionis Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to IONIS-HTTRx for the treatment of people with Huntington's disease (HD). This PRIME designation means this potentially disease-modifying drug for people with Huntington's disease to regulatory approval faster. This is exciting news! Read the full press release.